NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
IPO Year: 2022
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Profusa, Inc. (0001859807) (Issuer)
3 - Profusa, Inc. (0001859807) (Issuer)
Fastest customizable press release news feed in the world
New York, NY, Dec. 26, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") indicating that (i) the Staff has determined that the Company's securities will be delisted from The Nasdaq Stock Market; (ii) trading of the Company's Common Stock, Rights, and Warrants will be suspended at the opening of business on December 27, 2024; and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing on The Nasdaq Stock Market. Pursuant to
New York, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2024, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). This notification has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the
New York, NY, Sept. 13, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") granting the Company an exception to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). Pursuant to the terms of the exception, the Company must file its Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 and June 30, 2024 on or prior to October 14, 2024. If the Company does not satisfy the terms of the exception, the
New York, NY, June 07, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended March 31, 2024, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). This notification has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the N
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- NorthView Acquisition Corp (NASDAQ:NVAC) ("NorthView"), a publicly-traded special purpose acquisition company, and Profusa, Inc. ("Profusa"), a digital health company that is pioneering the next generation of personalized medicine, announced that NorthView filed a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on January 25, 2023. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previously announced Business Combination Agreement between NorthView and Profusa. Although the Registration Statement has not yet become ef
New York, New York, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa"), a digital health company that is pioneering the next generation of personalized medicine and NorthView Acquisition Corp. "NorthView") (Nasdaq: NVAC), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the "Business Combination Agreement") on November 7, 2022 that will result in Profusa becoming a publicly listed company. Upon closing of the transaction, NorthView will be renamed "Profusa Inc." (the "Combined Company"). Profusa is based in Emeryville, CA and is a digital health company that is pioneeri
8-K - Profusa, Inc. (0001859807) (Filer)
DEF 14C - NorthView Acquisition Corp (0001859807) (Filer)
CERT - NorthView Acquisition Corp (0001859807) (Filer)
8-A12B - NorthView Acquisition Corp (0001859807) (Filer)
425 - NorthView Acquisition Corp (0001859807) (Subject)
8-K - NorthView Acquisition Corp (0001859807) (Filer)
25-NSE - NorthView Acquisition Corp (0001859807) (Subject)
424B3 - NorthView Acquisition Corp (0001859807) (Filer)
EFFECT - NorthView Acquisition Corp (0001859807) (Filer)
S-4/A - NorthView Acquisition Corp (0001859807) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G - NorthView Acquisition Corp (0001859807) (Subject)
SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)
SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)
SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)
SC 13G - NorthView Acquisition Corp (0001859807) (Subject)
SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)
SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)
SC 13D - NorthView Acquisition Corp (0001859807) (Subject)
SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)